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Abstract
Cytomegalovirus (CMV) infection represents a vital complication after Hematopoietic Stem Cell Transplantation (HSCT). We
screened the entire CMV proteome to visualize the humoral target epitope-focus profile in serum after HSCT. IgG profiling
from four patient groups (donor and/or recipient +/2 for CMV) was performed at 6, 12 and 24 months after HSCT using
microarray slides containing 17174 of 15mer-peptides overlapping by 4 aa covering 214 proteins from CMV. Data were
analyzed using maSigPro, PAM and the ‘exclusive recognition analysis (ERA)’ to identify unique CMV epitope responses for
each patient group. The ‘exclusive recognition analysis’ of serum epitope patterns segregated best 12 months after HSCT for
the D+/R+ group (versus D2/R2). Epitopes were derived from UL123 (IE1), UL99 (pp28), UL32 (pp150), this changed at 24
months to 2 strongly recognized peptides provided from UL123 and UL100. Strongly (IgG) recognized CMV targets elicited
also robust cytokine production in T-cells from patients after HSCT defined by intracellular cytokine staining (IL-2, TNF, IFN
and IL-17). High-content peptide microarrays allow epitope profiling of entire viral proteomes; this approach can be useful
to map relevant targets for diagnostics and therapy in patients with well defined clinical endpoints. Peptide microarray
analysis visualizes the breadth of B-cell immune reconstitution after HSCT and provides a useful tool to gauge immune
reconstitution.
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Introduction
Patients after hematopoietic stem cell transplantation (HSCT)
remain at increased risk to cytomegalovirus (CMV) disease despite
advances in clinical management [1]; a similar situation is true for
patients after solid organ transplantation [2]. Protective immune
responses directed against CMV are predominantly mediated by
CD8+ T-cells targeting either CMVpp65 or immediate early (IE)-
1 proteins [3]. The importance of specific antibodies (Abs) as part
of the immune protection against CMV has been controversial in
the stem cell transplant setting [4–7], yet anti-CMV directed
serum antibodies may be clinically relevant in the post-transplant
setting in the absence of antibody producing B-cells due to the
half-life of serum IgG of 40–60 days. CMV targets recognized by
serum IgG include surface-exposed virion glycoproteins, e.g.
glycoproteins B (gB), gH, and gM/gN [8–10]. HSCT recipients
frequently lose specific antibodies after HSCT [11–13] and the
functional recovery of B-lymphocytes after HSCT may take up to
2 years [14,15].
The aim of this study was to map the CMV epitope IgG
recognition pattern in an unbiased way to answer unmet clinical
needs: i) target proteome mapping is currently being performed to
decipher biologically relevant epitopes in CMV vaccine develop-
ment, i.e. prevention of maternal cytomegalovirus infection [16].
Identification of biologically relevant CMV epitopes may aid to
develop improved strategies to boost anti-CMV directed immune
responses in CMV-discordant transplant situations. ii) Post-HSCT
vaccination CMV-strategies lack epitope recognition patterns
which would help to differentiate between already existing anti-
CMV humoral responses and new CMV epitope recognition
patterns associated with CMV infection(s) or CMV vaccines. iii)
CMV2 epitope mapping may help to decipher the quality of
immune responses in CMV-discordant transplant recipients; iv)
Mapping anti-CMV humoral reactivity will aid to reflect the
breadth of B-cell immune-reconstitution in transplant recipients
and possibly perturbations in the B-cell compartment associated
with graft-versus-host-disease (GVHD) [17].
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CMV – recognition mapping could be performed in different
ways, e.g. with a selected set of target CMV proteins or
alternatively, with a more comprehensive ‘omics’ approach which
enables an unbiased view of humoral immune reactivity [18]
including peptide microarray platforms. Such unbiased approach-
es helped to successfully decipher antibody signatures in infectious
disease, e.g. in the development of yellow fever vaccination [19]
and a system biology approach was instrumental to map protective
immune responses in seasonal influenza [20].
We took advantage of peptide-microarray technology to gauge
the global anti-CMV epitope recognition pattern in order to
understand i) when the humoral immune response against CMV is
formed in a post-transplant setting ii) if the CMV status impacts on
the epitope focus based on the CMV status of the donor/recipient
at the time of transplantation and iii) whether most of the CMV
epitope specific IgG responses are common or ‘private’ for each
individual.
Materials and Methods
Patient samples and peptide microarray slide preparation
The Stockholm regional ethical review board approved the
study (Ref 2007/735-31/1). Each patient agreed to the study and
signed the informed consent form, which is on file at the Dept. of
Hematology (Prof Ljungman), Karolinska University Hospital,
Stockholm, Sweden. 54 plasma samples were selected from 18
HSCT-patients (pat A to T); the patients had not received
intravenous immunoglobulin infusions; clinical information is
provided in Table S1. We recruited additional patients, designated
as P1–7, also listed in Table S1, from whom we had sufficient
matching peripheral blood mononuclear cells (PBMCs) available
to test for T-cell reactivity against CMV peptide targets identified
by antibody reactivity. All patients received conventional myeloa-
blative conditioning, i.e. cyclophosphamide (Cy) at 60 mg/kg for
two days in combination with fractionated TBI (FTBI) at 3 Gy/
day for four days (n = 15), or busulphan (Bu) at 4 mg/kg/day for
four days; RIC (reduced-intensity conditioning) was provided to 6
patients [21]. Immunosuppressive treatment for GVHD prophy-
laxis consisted of cyclosporine (CsA) in combination with a short
course of methotrexate (MTX). Patients with an unrelated donor
or a non-malignant disease received anti-thymocyte-globuline
(ATG, Thymoglobulin, Genzyme, MA, USA for 2–4 days during
conditioning [22]. During the first month, blood CsA levels were
kept at 100 ng/mL in patients with malignancies when a sibling
donor was used and at 200–300 ng/mL when an unrelated donor
was used. Higher CsA levels were also used for patients with non-
malignant disorders regardless of the donor type. In the absence of
GVHD, CsA was discontinued after three to six months for
patients with malignancies and after 12–24 months for patients
with non-malignant disorders. In vitro T-cell depletion was not used
and no patient received anti-CD20 (rituximab) treatment. Patients
were monitored weekly in peripheral blood for HCMV DNA with
a real-time polymerase chain reaction (PCR) [23,24] for the first
hundred days after HSCT.
Serum samples from CMV-negative recipients with CMV-
negative donors (D2R2) were used as negative controls and
compared against the other groups (D+R+, D+R2 and D2R+);
each consisting of samples from 5 patients, except for the D+R2
group (four patients). Serum samples from each patient were
selected from three different time points, i.e. +6, +12 and +24
months after HSCT. Peptide microarray slides were incubated
with serum and antibody binding to individual peptides was
identified by a secondary reagent as described earlier [25,26].
Slides with overlapping peptides covering the whole proteome
of HCMV (see Table S2) were manufactured by JPT, Berlin
Germany. The slides consisted of two identical subarrays, each
with 17496 spots arranged in 24 blocks of 729 spots arranged in
columns and rows of 27. The peptide spots represented 17174
unique peptides, 305 control spots (4 repetitions each of IgG, IgA,
IgM, and IgE), 268 negative controls and 31 other control spots.
All slides belonged to the same batch (a representative example is
provided in Fig. 1; CMV proteins with their accession numbers
are listed in the Table S2). The choice of CMV targets printed on
the chip was of critical importance in gauging the diversity of the
humoral recognition pattern. Chee and coworkers [27] estimated
that AD169 has 208 ORFs of which several are repeated (TRL1–
14 and IRL 1–14). Therefore, we choose only TRL 1–14 and not
IRL 1–14. Later studies from. Murphy and coworkers [28],
examining sequences of clinical HCMV strains, showed that the
number of protein-coding ORFs range from 165 ORFs, that are
conserved between clinical CMV isolates, up to 252 potentially
functional ORFs. Note, that an ORF was considered a coding
ORF if it encoded a polypeptide of 100 amino acids or more and
did not overlap a larger ORF across more than 60% of its length.)
We choose 214 ORFs in the current CMV chip layout, All ORFs
from AD169 were selected plus 19 additional ORFs from the
Toledo strain (discovered to be missing in the AD169 genome) and
3 additional ORFs from the Town strain. Therefore, there was no
premeditated choice of ORFs. We used the identical ‘template’,
i.e. ORFs from AD169 in order to visualize differences in B-cell
epitope recognition between different groups of patients, based on
their CMV donor/recipient serotype.
Slide scanning and analysis
Slides were scanned at two wavelengths: 532 and 635 nm with a
GenePix 4000B microarray scanner (Axon Instruments) and
images were saved in .tiff and .jpg formats. GenePix Pro 6.0
software and GenePix Array List (.gal) files were used to analyze
images with circular feature alignment using the following criteria
to flag spots with non-uniform foreground or background signal
for IgG detection:
F635Mean½ w1:5 F635 Median½ ð Þð ÞAND F635Median½ w40ð Þ
OR
B635Mean½ w 1:5B635Median½ ð Þð ÞAND B635Median½ w40ð Þ
F designates the ‘foreground’ and B the ‘background’ fluorescence
intensity measured at 635 nm wavelength. In addition, GenePix
categorized spots as ‘‘empty’’, ‘‘not found’’, ‘‘bad’’ or ‘‘good’’.
Each sub-array was converted to a digitized image and saved as a
.gpr (GenePix Result) file. To analyze the IgG responses, the
median fore- and background intensities for the 635 nm wave-
length from individual spots were used. All .gpr files were saved in
a common folder and imported into R software for subsequent
analyses.
Data quality assessment, data reduction, identification and
removal of false positive peptide responses from slides were
performed as previously reported [25]. Data for each of the five
groups of slides (IgG responses from the four CMV serological
transplant combinations and IgG from six control slides, i.e. buffer
and secondary antibody for IgG detection, without clinical
samples) were arranged in a matrix with identifiers for slide,
subarray, and block, and these master datasets were used in all
analyses described below.
CMV Proteome Peptide Microarray Analysis
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Statistical analysis
After pre-processing and normalization of peptide responses (as
described [25]), we used three different statistical methods: (i) PAM
(Prediction Analysis for Microarrays) [29], a predictive analysis
which performs sample classification from peptide recognition
data providing a list of significant peptides whose response level
characterizes each diagnostic class. Compared to other differential
recognition analysis methods, PAM is highly selective and allows
examining in detail each time point of consecutive serum testing.
This reveals only the peptide target with good predictive power
associated with the differentiation of the patient groups; (ii)
‘exclusive recognition analysis’ (ERA) of epitopes predicted by
PAM. The latter approach identifies epitopes recognized in serum
from individuals exclusively in one group but never in serum from any
individual in a control group, i.e. in the current report the
‘reference’ D2R2 patient group (termed ‘exclusive’ epitopes).
The peptide recognition pattern in this D2R2 ‘reference’ group
is listed in the Table S3A/B and the serum recognition pattern
concerning commonly shared and ‘private’ epitopes are shown in
Figure S1.
Finally, (iii) MaSigPro (Microarray Significant Profiles) [30] was
used to follow the dynamic changes in the peptide recognition
pattern over time comparing different (patient) groups. This
method identifies peptides with significant temporal recognition
changes and significant differences between experimental groups
via a two-step regression strategy. By using the coefficients
obtained in the regression model, significant peptides with similar
recognition patterns are then clustered together to visualize the
results (k-means clustering, Ward’s method).
The advantages of using both PAM and MaSigPro analysis is
the ability to identify CMV epitopes which would differentiate the
patients groups (defined by their CMV status, based on donor and
recipient serology) at each time point with statistical robustness.
Furthermore, the use of PAM and MaSigPro allows to follow
dynamic changes of serum antibody reactivity over time reflecting
the evolution of the transplanted donor immune system in the
host. This is usually performed using a selection of different
ELISA-based target assays, yet the humoral recognition pattern
using peptide microarray technology allows to appreciate serum
reactivity to thousands of epitopes simultaneously.
In order to define a peptide response as detectable or non-
detectable, we calculated a cutoff value based on the mean plus 2
Figure 1. Overview of HCMV peptide microarray chip analysis. The microarray chips (left) consists of two identical subarrays, each with 17496
spots arranged in 24 blocks of 729 spots arranged in columns and rows of 27. The peptide spots represented 17174 unique peptides, 305 positive
control spots (4 repetitions each of IgG, IgA, IgM, and IgE) and 268 negative controls. Screenshot (right, top) and closeup (right, bottom) of empty
spots, positive spots and a positive response, detecting an serum Ab-peptide complex.
doi:10.1371/journal.pone.0089648.g001
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standard deviation units of the normalized negative controls
(0.2947). The use of this detection limit enables to determine
which set of peptides is mutually excluded between each pair of the
comparison groups in the ‘exclusive’ peptide analysis. If a peptide
response is above the detection limit for all peptide responses in
one (test) group, but below the detection limit in the reference
group, the peptide is considered to be exclusively detectable in the
test group.
The gal file (GenePix Array List) was used to identify the
original protein origin of the identified peptides. The peptide
responses were ranked by i) the strength of their response and ii)
the number of replicates (x/n) in which the peptides were
recognized by serum antibody binding. We classified the CMV
peptides according to their function of the protein from which they
derived (c = capsid, m = matrix or tegument, e = envelope,
gp = glycoprotein, r = DNA or regulatory, o = other, unk = un-
known).
GenBank files of the complete human herpesviruses (HHV)
genomes were downloaded from www.ncbi.nlm.nih.gov/nuccore/
: Herpes Simplex virus-1 (HSV-1 or HHV-1, accession number:
AB618031.1), Herpes Simplex virus-2 (HSV-2 or HHV-2,
accession number: NC_001798.1), Varicella-Zoster virus (VZV
or HHV-3, accession number: NC_001348.1), Epstein-Barr virus
(EBV or HHV-4, accession number: NC_009334.1), HHV-6A
(accession number: NC_001664.2), HHV-6B (accession number:
AB021506.1), HHV-7 (accession number: NC_001716.2) and
HHV-8 (accession number: AF148805.2). Using a custom made
script, incorporating PyCogent [31], translated regions from the
GenBank files were extracted and one FASTA file was created for
each herpesvirus as a reference database to create eight
herpesvirus protein databases. A data file was created containing
a list of i) all CMV peptides found in the top layer of the ‘exclusive’
peptide analysis (with the peptide being recognized in 4 or 5
patients in one group but never in the D2R2 group), ii) peptides
found in the PAM analysis and iii) all peptides intersected in both
PAM and the ‘exclusive recognition analysis’. This list of CMV
peptides was searched and compared against herpesvirus protein
databases via the BLASTP program (http://blast.ncbi.nlm.nih.
gov/Blast.cgi?PAGE = Proteins).
CMV specific antibody detection by RecomBlot and ELISA
Qualitative in vitro testing for detection and identification of IgG
antibodies against CMV were performed using a commercially
available Western Blot (RecomBlot CMV IgG test, Mikrogen,
Neuried, Germany). Serum antibody responses in serum samples
from patient A–D in the D2R2 group were compared to serum
reactivity from patients in the D+R+ group before and +6 months
after HSCT. CMV antibody responses in sera from seven
additional HSCT-patients (pat 1–7) were also mapped at +6
months post-HSCT since we had sufficient numbers of PBMCs
(from the identical time point) available from these patients to be
tested for CMV peptide target reactivity by cytokine production
analysis). Both patient groups (A to T and 1–7) were tested with
the identical batch of CMV high content peptide microarray
slides. IgG responses were additionally tested using a commercially
available ELISA (Platelia) CMV IgG, from BioRad, Mames-la-
Coquette, France. The output of this ELISA are anti-CMV
antibody titers; a titer of ,0,25 AU/mL is negative (absence of
acquired immunity, recent infection cannot be excluded), the
result is determined to be ‘equivocal’ with a titer of 0,25–0,5 AU/
mL (suggesting a recent infection of the patient; requires re-testing
in 2 weeks) and the titer of .0,5 AU/mL reflects a positive result,
i.e. a past CMV-infection. This does not exclude a recent infection
and an anti-CMV IgM ELISA may be required in the latter case.
Intracellular cytokine staining
Cytokine production by intracellular cytokine staining (ICS) was
analyzed in PBMCs from 5 patients harvested at 6 months after
HSCT as described by Magalhaes et al 2010 [32]. Cells were
stimulated with peptide mixes from CMV, covering the entire
protein UL94 (P168000), CMV UL55 glycoprotein B (P06473),
CMV UL99 p28 (P13200) and CMVpp65, all purchased from
JPT Peptide Technologies, GmbH, Berlin, Germany. Medium
and PMA/ionomycin (1 mg/ml) from Sigma-Aldrich were used as
negative and positive controls, respectively. For quality reasons, all
PBMC samples were run twice. The following antibodies were
used to gauge intracellular cytokine production: PE-conjugated
anti-IL-2 (MQ1-17H12), PE-Cy7-conjugated anti-IFN-c (B27),
and APC-conjugated anti-TNF-a, all obtained from BD Biosci-
ences, the PE-conjugated anti-IL-17 antibody (eBio64DEC17) was
purchased from eBioscience (San Diego, CA). Cells were analyzed
using a Gallios Beckman Coulter flow cytometer and data analysis
was performed using Kaluza software.
Results
CMV infection
Serum samples from patients after HSCT (Table S1), sampled
weekly from the time of hematopoietic stem cell infusion (time
point 0) until day 100 were tested for CMV DNA. Four out of five
individuals in the D2R+ group, one out of five in the D+R2
group and in three out of five individuals in the D+R+ group
tested positive for CMV DNA at a single time-point within the 100
day observation period after HSCT. In the D2R2 group, one
patient developed a primary CMV infection at 8 months after
HSCT and was therefore removed from the analysis (since the
D2R2 served as the ‘control cohort’) No patient developed CMV
disease and no pre-emptive antiviral therapy was provided since
the viral load was below the intervention limit. ELISA-based
analysis of serum samples to gauge humoral IgG immune
responses (at 6, 12 and 24 months after HSCT) revealed that
samples from all recipients in the D+/R+, as well as in the D2/
R+ group tested positive (for all three time points after HSCT) for
CMV. Serum samples from the D2/R2 (reference) group tested
negative for all time points after HSCT (except for a single patient
that experienced CMV infection at 12 month after HSCT, the
serum samples from this individual was therefore removed from
the reference group, see above). Serum samples from the D+/R2
group showed a different CMV reactivity pattern after HSCT:
samples from 2 individuals tested negative for CMV IgG (at all
time points, i.e. 6, 12 and 24 months after HSCT) and serum
samples from 2 individuals (who tested previously negative at the
time of HSCT) tested positive at 6, 12 and 24 months after HSCT.
We could not test serum samples from the fifth patient in this
cohort, since there was no biological material available.
Chimerism analysis
PCR amplification of variable number of tandem repeats was
used to evaluate donor/recipient chimerism in CD3+, CD19+ and
CD33+ cells [33]. All patients were complete donor chimeras for
CD19+ B-cells at 6 months.
Differential CMV peptide recognition defined by the CMV
status of the recipient
Serum samples were tested for CMV peptide reactivity (Fig. 1)
and several peptide groups could be identified: i) peptides only
recognized in serum from some individuals and CMV peptides
commonly recognized in serum from individuals in each group
(based on donor/recipient CMV reactivity defined by the time of
CMV Proteome Peptide Microarray Analysis
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HSCT, see Figure S1). Strongly recognized CMV peptide epitopes
(based on fluorescence intensity) were commonly recognized in
each patient group, i.e. in serum from each individual patient in
the respective donor/recipient group based on the CMV status at
the time of transplantation. ii) We identified CMV peptides
recognized in serum from all individuals in the respective patient-
group, but never in serum from any individual in the (reference)
D2R2 group (Fig. 2 and Table 1).
In addition to peptide recognition that clusters according to the
CMV status of the donor or the HSCT recipient, we identified a
distinct CMV recognition pattern common to all study subjects:
372/17496 peptides (see Table S4), defined by PAM, were
differentially recognized by serum IgG at all time points after
HSCT. These CMV epitopes were recognized in serum from both
the test- and the reference (D2R2) group with a constant strong
recognition in one group (4/4 or 5/5 individuals) and constant
weak recognition in the other groups (Fig. 3). We analyzed then if
these unique peptide targets are recognized in serum from all
individuals (from a patient group), but never in any individuals
from the D2R2 group. This intersection of PAM and the
‘exclusive recognition analysis’ allowed to identify a few CMV
epitopes with the power to differentiate between patient groups
(defined by CMV reactivity of the donor/recipient at the time of
HSCT): 48 CMV peptides were uniquely recognized at different
time points after HSCT that allowed to associate the peptide
recognition pattern to the CMV profile of the donor or the
recipient (Table 2).
The dynamics of unique CMV immune recognition in
serum is associated with the serological CMV status of
the donor and recipient
Uniquely recognized CMV peptides, i.e. defined only in a
particular patient group but never in the control group (‘exclusive
recognition analysis’) in serum from individuals in the D2R+,
D+R2 or D+R+ (but never in D2R2), changed over time
(Fig. 2). The ‘exclusive recognition analysis’ segregated best at 12
months after HSCT for the D+/R+ group (versus D2/R2).
Peptides were derived from the targets UL123 (IE1), UL99 (pp28),
UL32 (pp150). This recognition pattern changed at 24 months
after HSCT to the IgG recognition of two strongly recognized
peptides derived from UL123 (IE1, but a different epitope as
compared to the 12 months analysis) and a target epitope from
UL100.
CMV epitope serum reactivity in the D2R2 group and the
D+R2 group exhibited a ‘contraction’ of the number of CMV
peptides that were exclusively recognized at 12 months after
HSCT. This opposite was found to be true for the ‘expansion’ of
CMV epitopes recognized in serum from the D+R+ group (Figure
S1). Almost 17% (8 out of 48) of the most strongly recognized
CMV epitopes in this intersectional analysis originated from CMV
Figure 2. Differential CMV peptide recognition after HSCT segregates with the CMV status of the donor and recipient. Comparisons
between serum reactivity in the D+ and D2 groups and R+ and R2 groups reflecting the number of CMV epitopes predicted by the ‘exclusive
recognition analysis. Some peptides are uniquely recognized in serum from all individuals in each test group (but never in the control group, D2/
R2). The list of epitopes is provided in Table 1.
doi:10.1371/journal.pone.0089648.g002
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Table 1. Epitopes predicted by the Exclusive RECOGNITION
analysis.
EPITOPE
HCMV
ORF EPITOPE
HCMV
ORF
6 months after HSCT KRCLVPEVFCTRDLA UL29
Serological group D2R+ LRDLGHRVQTYCEDL UL77
TRVFFSPCAPHVAFI J1I PVGSMYRGSDALPAG US34
HNVTREVNVRKRAYL UL56 PRNVMTHEEAESRLY UL36
LFATTLFIGYMPIHC UL125 GGDWADSASDFDADC TRL 1
PLLAYAYFRSVFYVI UL57 GGGGGLDRNSGNYFN UL44
(pp50)
SACTWTSCTSLSPCS US20 MELDSVEEEDDFGAS UL45
WSFGMLFFIWAMFTT UL100 VALFPSSPPSLKDSC UL21
RVSAFVAYAVARNRR UL70 FDDYGNTKSYLGAYT TRL 3
CFLRTCLRLVTPVGF UL102 DDAPPTYEQAMGLCP UL42 rev
GTTGSYTPPQDGSFP UL139
Toledo
TRFQGPDSMPSTSYG UL35
ITTYNEYEILNYFDN UL1 KEKYEQHKITSYLTS UL44
(pp50)
TPCPNGTYVSGLYNC UL144
Toledo
DESGRPRRIANRIGD US22
ARVFCLSADWIRFLS UL114 IRSSLILYATETLIY US14
DKLIAWMTWLSSRAT US17 TTPPMIDLTSHHRPL UL117
YLPKDAFFSLLGASR UL80 LRLLACPDRPIIGDT UL25
FICRDNCTLSDQFTL US16 AVVWGNARLDALMSA UL45
RRITRPRQIPLCTGV UL49 SMSLGARDAELYHLP UL104
TWTLFVACNGVAWEH US14 HDDGPGLDNDLMNEP UL44
(pp50)
TLQHMSKKQESIATI UL143
Toledo
ELPHTASLRALAGCM UL23
DLLREVQRNLTRTMA US17 AGGAAAGPRPPPPPM UL50
SYPASYGAPVVGYDQ UL80
Serological group D+R2 SVEEEDDFGASLCKV UL45
GEDDVLATIRNTLSA UL150
Toledo
NLSLPPSNALSSKDY UL 9
CFLRTCLRLVTPVGF UL102 KAVLGLNAACAVYDH UL49
YCDLLRVGYFGHLNI UL43 rev LLIQDGMYGRGEKEL UL121
LSDVTQRRNRPLRCL UL35
Serological group D+R+ EREEDTLREMALKAF UL25
SQKPVLGKRVATPHA UL32
(pp150)
LERRSHEELVLCPPE UL88
TTSTSQKPVLGKRVA UL32
(pp150)
SSTEGNWSVTNLTES UL20
RACRPFDHMPAADFR US22 GMSLNQSTRDISYMG UL100
SLKPTLGGKAVVGRP UL32
(pp150)
KVPEDSEPQCNPLLP UL18
HRANETIYNTTLKYG UL55 (gB) LAQFRGTMDDDEAAL UL31
EVHDALLFHYEHGLG UL77 DTLREMALKAFMEAN UL25
VLSHHDSLESRRLRE UL100 DFMRDFTQLLESCDI UL52
STFTTVYSTFNTSYA TRL12 SKATRRTSPRYYPPS IRL14
HDSLESRRLREEEDD UL100 GLAWTRQQNQWKEPD UL83
(pp65)
APPSPVKGRGSRVGV UL32
(pp150)
AADYLCCDDTLEAVG US22
AFLHYFTTLKQYLRN UL18 SVGVNSKVRACVIGY UL105
CHTETTIIRFKETNT TRL12 IRYIPATQGDVYHGR UL 3
Table 1. Cont.
EPITOPE
HCMV
ORF EPITOPE
HCMV
ORF
TTETNMTTARESSVH UL132 SMHCRSRHQRTPPSA UL150
Toledo
KLPYSITVTYDHRTS UL107 IPNDVSESFERYKEL UL53
AFRFTPANTTTNSST UL20 YDDESWRPLSTVDDH IRS1
CFLRTCLRLVTPVGF UL102 SGNAYNHTIDTCKNT UL20
GRASVVFVHHVVKYS UL45 IPNRIRYIPATQGDV UL 3
VERLLATSDGLYLYN UL97 NHGAGGTAAVSYQGA UL54
ITTYNEYEILNYFDN UL 1 EDFAHQCLQAAKKRP US 6
EEAVNLLDDTDDSGG UL132 SVPVSQRMEHGQEET UL105
NVTFRGLQNKTEDFL UL 4
(gp48)
EDEEGGEKGGDDPGR UL52
DTVLLMHFFYTHYRS UL46 EGGWGGEEGEDDVLA UL150
Toledo
YCDLLRVGYFGHLNI UL43 rev ALCFCLLCEAVETNA UL116
RVSAFVAYAVARNRR UL70
VGFDRVPQYDFLISA UL45 24 months after HSCT
SQDHVQIVYGSTRIC UL117 Serological group D2R+
ARVFCLSADWIRFLS UL114 LENVTVYPTYDCVLS UL77
TWTLFVACNGVAWEH US14 PPLPGHARRPRRKRC UL29
SACTWTSCTSLSPCS US20 PGEPLKDALGRQVSL UL99
(pp28)
NRKASGTGVAAVGAY UL89 TPEQSTPSRIRKAKL UL32
(pp150)
LKDALGRQVSLRSYD UL99
(pp28)
12 months after HSCT SQKPVLGKRVATPHA UL32
(pp150)
Serological group D2R+ FGTTPGEPLKDALGR UL99
(pp28)
YLHFSAYKLLKKIQS UL35 VGVPSLKPTLGGKAV UL32
(pp150)
IPNDVSESFERYKEL UL53 NPANWPRERAWALKN UL32
(pp150)
AQLDLEADPTAREGE UL35 PRHTFDMDMMEMPAT UL42 rev
DEKNIFTPIKKPGTS UL32
(pp150)
TSPNALLPEWMDAVH UL136
Toledo
RRDSAWDVRPLTETR UL32
(pp150)
FDMDMMEMPATMHPT UL42 rev
IFTPIKKPGTSGKGA UL32
(pp150)
WSFGMLFFIWAMFTT UL100
TPEQSTPSRIRKAKL UL32
(pp150)
AFIRRRRPPHHTQLV J1I
SQKPVLGKRVATPHA UL32
(pp150)
IFTEHVLGFELVPPS UL115
AKRKMDPDNPDEGPS UL122
(IE2)
HYLMYSHTNNECVGE US27
LSDVTQRRNRPLRCL UL35
TTTAELTTEFDYDED US28 Serological group D+R2
QKKISQRPPTPGTKK UL99
(pp28)
GMRAVSQFLVTHPLG US33
WLNFRVDLFGDEHRR UL35 FSGNGVERSLNVSSM UL57
VRKLMKRGARLRHDS UL38 AFIRRRRPPHHTQLV J1I
CQEYLHPFGFVEGPG UL36 KCRITEPITMLGAYS TRL10
EFDYDEDATPCVFTD US28 NFEAVLARGMHVEAG UL93
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pp150, five of 48 (10.4%) from CMV pp28 and 8.3% from CMV
IE1. Other epitopes originated from the CMV gene products gH,
UL100 and other structural as well as non-structural CMV
proteins (see Tables 1 and 2).
Significant changes in humoral CMV reactivity over time
defined by maSigPro segregate patient groups
The serum CMV peptide recognition patterns for each time
point after HSCT for the different patient groups were compared
using the program MaSigPro (for details, see methods section). We
searched for CMV peptide targets, that would allow the
segregation of each patient group if all time points for the patient
groups were considered simultaneously in the analysis. Significant
differences were identified for 143 CMV epitopes in the dynamic
changes of peptide recognition over time between the respective
groups and the reference group D2R2 (see Table S4). The
resulting CMV epitopes were grouped in clusters according to the
peptide recognition profiles and according to the average serum
Table 1. Cont.
EPITOPE
HCMV
ORF EPITOPE
HCMV
ORF
VTFEFVPNTKKQKCG UL44
(pp50)
HLQLRHALELQMMQD UL35
ERRIREGKIPMTFVD UL38 TNQYLIKGISYPVST UL75 (gH)
RTRVSLGHRVAFGCS UL 6 MPPPVAELCERGRDD US19
QNTVLITDQSREEFD UL89 VREEIPASDDVLFFV UL57
GTTGSYTPPQDGSFP UL139
Toledo
LQLDRLVFEAAQRGL UL87
RVINMKAALSSIAAS UL87 NLQARDASGLMFPII UL46
NRELPSLFCDCPGGG UL87 GYSAVFLLETEDAVT UL103
IWLGIPDSHNICQHE US13 DYVLKFLTRLAEAAT UL86
PTEISEATHPVLATM UL122
(IE2)
KFFVDRLCCETMIMG US26
QRQAVSRYSGWSTEY UL52
QHERPSLYHDLCRSC TRL12 Serological group D+R+
PLPPWLRKKKACALT UL37 RLPRPDTPRTPRQKK UL99
(pp28)
GGGGGLDRNSGNYFN UL44
(pp50)
Serological group D+R2 PAPPADIDTGMSPWA UL141
Toledo
VTKLYTSRMVTNLTV UL16 TPRHRRRPERSKTPD J1I
YRSGAGTFLVTHRHL US35 ESPVPATIPLSSVIV UL123
(IE1)
HDSLESRRLREEEDD UL100
Serological group D+R+ CQEYLHPFGFVEGPG UL36
RLPRPDTPRTPRQKK UL99
(pp28)
VLSHHDSLESRRLRE UL100
ESDEEEAIVAYTLAT UL123
(IE1)
YAEKHGGRIDGVSLL US18
MFLGYSDCVDPGLAV UL 5 SVSNAPPVASPSILK UL32
(pp150)
YPAVTTVYPPSSTAK UL32
(pp150)
TTVYPPSSTAKSSVS UL32
(pp150)
EFDYDEDATPCVFTD US28 LREEEDDDDDEDFED UL100
MADSVCLPPCLSPDM UL45 GLLRDPRLMNRQKER UL113
IRKPPWLMEQPPPPS IRS1 AFLHYFTTLKQYLRN UL18
PNCCQVSVDRSRVPE UL30 FLGARSPSLEFDDDA UL32
(pp150)
RNGATFSKGDIEGNF US30 RTPRQKKISQRPPTP UL99
(pp28)
LYKGTDGLPTTDYLS UL10 TPEQSTPSRIRKAKL UL32
(pp150)
QTYCEDLEGRVSEAE UL77 APGPTVANKRDEKHR UL122
(IE2)
MESSAKRKMDPDNPD UL122
(IE2)
SYTPPQDGSFPPPPR UL139
Toledo
HDSLESRRLREEEDD UL100 QMNHPPLPDPLGRPD UL122
(IE2)
PDTPRTPRQKKISQR UL99
(pp28)
SLSDGAPLDNGTLTA US20
AKRKMDPDNPDEGPS UL122
(IE2)
FLPQSPGLPPTEEEE UL82
(pp71)
SQKPVLGKRVATPHA UL32
(pp150)
LKDALGRQVSLRSYD UL99
(pp28)
Table 1. Cont.
EPITOPE
HCMV
ORF EPITOPE
HCMV
ORF
VLSHHDSLESRRLRE UL100 NSGNYFNDAKEESDS UL44
(pp50)
QQQQRHAAFSLVSPQ UL32
(pp150)
QRGDPFDKNYVGNSG UL44
(pp50)
IGPVDRSSLYEANPE UL29 REPTKDLDDSFDYLV UL78
CQEYLHPFGFVEGPG UL36 GLDRNSGNYFNDAKE UL44
(pp50)
FLGARSPSLEFDDDA UL32
(pp150)
EDTSIYLSPPPVPPV UL99
(pp28)
DEKNIFTPIKKPGTS UL32
(pp150)
HPSPMIAAAPPAQPP UL69
TASGEEVAVLSHHDS UL100 SYPASYGAPVVGYDQ UL80
QKKISQRPPTPGTKK UL99
(pp28)
DPTYDELPSRPPQKH IRS1
RTPRQKKISQRPPTP UL99
(pp28)
NPANWPRERAWALKN UL32
(pp150)
DDDEDPTYDELPSRP IRS1 TTPPMIDLTSHHRPL UL117
TTTAELTTEFDYDED US28 TSPNALLPEWMDAVH UL136
Toledo
ETRGDLFSGDEDSDS UL32
(pp150)
SLLTAVRRHLNQRLC IRS1
LFVGNLQARDASGLM UL46 LIVLIGQRGGIYCYD UL36
VTKATTFLQTMLRKE UL122
(IE2)
PRPPPLGRGRGAGGP IRS1
TTVYPPSSTAKSSVS UL32
(pp150)
MTLRTFLQTYFSSDK US15
TGNDGGGGDQIMGDK UL31 AFIRRRRPPHHTQLV J1I
PLCASEPEDDDEDPT IRS1 CDGPPGSPTDSARHM UL24
TPEQSTPSRIRKAKL UL32
(pp150)
SFAATLLHRYPINPS TRL 2
FGLRNCQFLAVGPDD UL45 TVPRRRSMPAPNGPL UL15
SHRPVCYNDTGDCTD US 6 PATIPLSSVIVAENS UL123
(IE1)
WLNFRVDLFGDEHRR UL35
The peptides presented are only detectable in serum from at least 4 out of 5
individuals in the respective group (D2R+, D+R2 or D+R+, 6, 12 and 24 months
post-HSCT) but never in the group D2R2 at 6, 12, and 24 months post-HSCT.
doi:10.1371/journal.pone.0089648.t001
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recognition signals. CMV epitope recognition patterns were
identified in each patient group (see example in Fig. 4; the entire
peptide list is provided in Table S5): 32 unique CMV epitopes
segregated D2R+ between D2R2 if all time points (up to 24
months) after HSCT were considered, 54 epitope segregated
D+R2 between D2R2, and 57 segregated the D+R+ group as
compared to the D2R2 control group. A Venn-diagram
describing the number of exclusive and shared epitopes showed
that 12 epitopes were commonly recognized in serum from all
three patient groups (at all time points after HSCT, Fig. 4). Thus,
these unique CMV peptide epitopes are capable of segregating the
CMV status of the donor and recipient; these peptides are also
commonly recognized in serum from patients up to 24 months
after HSCT as compared to the D2R2 control group. The CMV
epitope NGVWVVVFLVNVLIV, recognized in serum from all
three patient groups, is derived from the membrane protein US16
[34], a tropism factor that regulates, the pre-immediate-early
phase of the HCMV replication cycle.
Shift of CMV protein recognition focus over time
The origin of each individual target peptide defined by PAM
and maSigPro analysis (see above) was examined. The CMV
epitopes segregating each patient group are distributed among
different CMV proteins. The peptide targets, defined by antibody
reactivity, that segregated the patient groups (compared to the
D2R2 reference group) at 6 months after HSCT were directed
against CMV proteins with unknown function (40%), matrix
proteins (25%), glycoproteins (13%), regulatory proteins (12%),
capsid (5%), and envelope (1%) proteins. This pattern was
different at 24 months after HSCT: a higher proportion of
antibodies were directed against proteins with regulatory function
(21%). Thus, the source of uniquely recognized target epitopes was
different, dependent on the time point after HSCT.
Potential cross-reacting antibodies
Since the peptide sequences displayed as targets on the chip
were provided by 15 amino acid (aa) stretches, we searched for
identical epitopes which were at least 5 aa in length but we did not
allow any aa mismatches within these stretches. We identified
epitopes (using these filtering criteria) from related herpes virus
species that could give rise to cross-reacting antibodies: 42 out of
372 (12.4%) hits (identified in PAM) and 26 out of 248 hits (12.5%)
in the ‘exclusive recognition analysis’ showed at least a stretch of
five identical amino acid residues within the 15mer target epitopes
displayed on the microarray chip. A different situation was found
to be true for the intersection between PAM and the ‘exclusive
recognition analysis’: the number of CMV peptides, displaying five
identical aa residues between CMV and other herpervirus species,
was low, i.e. 3 out of 42 (7%) peptides shared a stretch of five
amino acid residues; most of these possible hits derived from
HHV-8: In PAM, 8.7% of the hits matched a protein originating
from HHV-8; in the ‘exclusive recognition analysis’, 16.1% (CMV
epitope) hits matched HHV-8. The intersection between PAM
and the ‘exclusive recognition analysis’ revealed that 60% of all
closely related epitopes were derived from the HHV-8 proteome.
Correlation of CMV specific antibodies defined by
Western Blot and peptide microarray technology
We examined the CMV-serological status pre-HSCT in the 4
patients in the D2R2 group and the patients in the D+R+ group.
Our results confirmed that all CMV-negative patients lacked IgG
against the linear CMV test antigens at all time points before and
after HSCT in contrast to the D+R+ group from whom all serum
samples tested positive by Western Blot analysis (data not shown).
A strong serum recognition in Western Blot analysis (targets gB1
and p150) from D+/R+ patients was associated with a high
number of linear peptide epitopes defined by peptide microarray
technology (see Figure S2).
IgG recognition is associated with CD4+/CD8+ cellular
target recognition and distinct cytokine production in
response to individual CMV targets
The cytokine profiles of CD4+ and CD8+ T cells were analyzed
upon stimulation with peptides covering the entire CMV pp65,
CMV UL94, CMV UL55 (gB) and CMV UL99 (p28) proteins.
We chose some of the peptide targets based on the situation that i)
a T-cell response had been described previously (i.e. CMV pp65,
gB) and ii) to test whether IgG CMV recognition (see Figure S3)
would guide the choice for CD4+ or CD8+ T-cell recognition of
other CMV targets. IL-2, TNF-a, IFN-c and IL-17a were
measured simultaneously on the single cell level to assess the
presence of antigen-specific polyfunctional CD8+ and CD4+ T
Figure 3. PAM analysis segregates CMV epitope responses. PAM visualizes the difference in antibody response against specific epitopes in
different patient groups: distinct CMV epitope are always strongly recognized in one patient group, and always weakly recognized in the control
group (or vice versa). Paradigm of weak antibody responses in patients in the D2R2 group (black dots) in all patients, yet strong recognition in
serum from all patients in the other serological groups (grey dots). A detailed listing of PAM-defined targets is provided in the Table S3.
doi:10.1371/journal.pone.0089648.g003
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Table 2. Intersection between PAM and the Exclusive Recognition analysis.
EPITOPE HCMV ORF Q-value
6 months after HSCT
Serological group D2R+
QPGENEVRPHAGVID UL102 0.0879
RACRPFDHMPAADFR US22 0.0466
GEVVNTMFENASTWT UL77 0.0661
Serological group D+R2
RACRPFDHMPAADFR US22 0.2054
NISNVTYNGQRLREF UL118 0.139
HNVTREVNVRKRAYL UL56 0.0624
YCDLLRVGYFGHLNI* UL 43 rev 0.025
HREKVLYLAIACFFG UL11 0.009
Serological group D+R+
SQKPVLGKRVATPHA* UL32 (pp150) 0.7497
TTSTSQKPVLGKRVA* UL32 (pp150) 0.4908
12 months after HSCT
Serological group D2R+
AQLDLEADPTAREGE UL35 0.0207
SQKPVLGKRVATPHA UL32 (pp150) 0.0036
Serological group D+R2
VTKLYTSRMVTNLTV* UL 11 0.0616
Serological group D+R+
PNCCQVSVDRSRVPE* UL 30 1.121
RLPRPDTPRTPRQKK* UL 99 (pp28) 0.8275
IRKPPWLMEQPPPPS* IRS1 0.5896
MFLGYSDCVDPGLAV* UL 5 0.4723
HDSLESRRLREEEDD UL100 0.3524
DESGRPRRIANRIGD US22 0.2426
ESDEEEAIVAYTLAT* UL123 (IE1) 0.2171
MESSAKRKMDPDNPD UL122 (IE2) 0.2167
PDTPRTPRQKKISQR UL 99 (pp28) 0.1748
TPEQSTPSRIRKAKL UL 32 (pp150) 0.0961
LSDVTQRRNRPLRCL UL 35 0.0875
RNGATFSKGDIEGNF* US30 0.0698
YPAVTTVYPPSSTAK* UL 32 (pp150) 0.0682
SQKPVLGKRVATPHA UL 32 (pp150) 0.0385
YDDESWRPLSTVDDH IRS1 0.0202
24 months after HSCT
Serological group D2R+
LKDALGRQVSLRSYD UL99 (pp28) 0.1663
SQKPVLGKRVATPHA UL32 (pp150) 0.1604
PGEPLKDALGRQVSL UL99 (pp28) 0.1357
FGTTPGEPLKDALGR UL99 (pp28) 0.1228
SLKPTLGGKAVVGRP UL32 (pp150) 0.0608
TRPFKVIIKPPVPPA UL122 (IE2) 0.0574
TSPNALLPEWMDAVH UL136 Toledo 0.025
Serological group D+R2
TNQYLIKGISYPVST* UL75 (gH) 0.4478
ERDWRRVIHDSHGLW US32 0.4154
AFIRRRRPPHHTQLV* J1I 0.333
DYVLKFLTRLAEAAT* UL86 0.2286
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cells upon stimulation with peptide pools from different CMV
proteins. The profile of one representative PBMC sample is shown
in Fig. 5. In general, CD8+ T cells displayed a polyfunctional
profile with co-production of IL-2, IFN-c and TNF-a. Stimulation
with pp65 showed that 25% of CD8+ T-cells exhibit co-
production of all four cytokines including IL-17a. In contrast,
CD4+ T cells showed a poly-functional cytokine production profile
with co-production of all four cytokines after stimulation with p65;
this was not found to be true for other CMV targets. Mono-
functional IL-2 producing cells were predominantly seen after
stimulation with CMV p65 and CMV UL55 (glycoprotein B)
peptides. We did not run statistics since the number of patient’s
samples (n = 5 patients) was too low. Cytokine production was also
seen also found in the negative control (stimulation only with
medium, no peptides); most likely due to GVHD and other
inflammatory processes after HSCT; yet these T-cell responses
showed a different profile as compared to the CMV antigen-
specific responses.
Discussion
Entire proteomes can now be screened for immune recognition
in the context of personalized medicine [35] and peptide
microarray technology has enabled to pinpoint clinically and
biologically relevant humoral target epitopes, e.g. for the
identification of tumor associated antigens (TAAs) [36], gauging
HIV vaccination [37], epitope reactivity in bacterial infections
[38,39], or targets in autoimmune diseases [39–42].
Due to the high resolution epitope-recognition matrix, peptide
arrays allow the description of both ‘common’ (i.e. present in all
patients with the same clinical endpoint) and ‘private’ (i.e. only in
individual patients) CMV specific humoral recognition patterns
[26]. This will be helpful in searching for anti-CMV specific B-cell
responses associated to clinical outcomes; it will also aid to
appreciate in more general terms the nature of the B-cell immune
reconstitution using the entire CMV proteome as a target matrix
to describe the dynamic nature of the immune response in
individuals over time [43]. Of interest, strongly recognized CMV
epitope targets appear to be shared among patients (Figure S1).
B-cell reconstitution after HSCT develops through certain
stages. Transitional B-cells (CD19+, CD24high, CD38high)
constitute only 4% of the circulating B-cells in adults, yet they
account for 50% of B-cells in cord blood and for the majority of B-
cells early after HSCT in the peripheral circulation. This B-cell
population decreases as newly mature B-cells are formed, usually
starting at 6 months after HSCT [44]. A large number of naı¨ve B-
cells contribute to the plasma Ig production, yet these Igs are
believed to be of too low-affinity to be detected using microarray
technology based on the assumption that a fluorescent-based Ig
array detects approximately 10 attomoles of IgG [45]. Differences
in the Ig recognition of CMV targets may stem from many
different sources: i) the plasma half-life of the IgG, ii) the pattern of
B-cell reconstitution, iii) the transfer of mature B-cells with the
graft, iv) stimulation of the developing B-cell repertoire by
commensal microbes, v) stimulation of B-cells by specific
pathogens and autoantigens, vi) the cytokine/inflammation milieu
including the nature of immune suppression, or the regimen used
for conditioning of the host.
The antibody profile against CMV was dependent on pre-
transplant defined serological groups (see Tables 1, 2). The
capacity to develop antibodies to previously not recognized
peptide targets was stronger in the CMV donor positive groups
(see Tables 1 and 2). Comparisons over time show that the
patterns of humoral responses changed after HSCT; our results
indicate that the early humoral response is not originating from
the transplanted donor immune system, but represents rather a
recipient derived response and is thereby a reflection of pre-
existing antibodies or persistent recipient B-cells [11,13]. To prove
this point, we examined in addition sera from patients pre-HSCT,
followed by serum analysis after HSCT. Comparison of pre-
Table 2. Cont.
EPITOPE HCMV ORF Q-value
FAALQEQGVEDFSLE UL57 0.0908
PRHTFDMDMMEMPAT UL42 rev 0.0886
RWKDNKQYGQVFMTD UL 8 0.0636
GMRAVSQFLVTHPLG* US33 0.0354
LQLDRLVFEAAQRGL* UL 87 0.0104
SVMLAKRPLITKPEV UL123 (IE1) 0.0014
Serological group D+R+
HDSLESRRLREEEDD UL100 0.2181
ESPVPATIPLSSVIV* UL123 (IE1) 0.0481
PDTPRTPRQKKISQR UL 99 (pp28) 0.1748
TPEQSTPSRIRKAKL UL 32 (pp150) 0.0961
The table lists peptides that were commonly defined by PAM (peptides with significant differences in the intensity of the response vs. the reference group D2R2) and
as well in the ‘exclusive recognition analysis’ (never above a threshold for detection in the D2R2 group). Peptides marked with a star (*) were above this threshold in all
patients in the respective group but never in serum from D2R2 patients. The average Q-value is the absolute difference between PAM Q-score for D2R2 and the Q-
score for each respective group. Higher average Q-value indicates the probability that the peptide is differently recognized between the respective group and the
D2R2 (reference) group.
At 6 months, possible cross-reactivity to serum IgG for the epitope QPGENEVRPHAGVID (HCMV UL102) and the aminoacid sequence from a DNA packaging tegument
protein UL17 from Herpes Simplex virus-1, which shows a matching alignment of 5 amino acids without any mismatch. Note at 12 months, a possible cross-reactivity of
serum IgG for the epitope AQLDLEADPTAREGE (HCMV UL35) and the aminoacid sequence from a protein from Epstein-Barr virus, RNGATFSKGDIEGNF (HCMV US30), the
Human herpesvirus-6A protein, the epitope YPAVTTVYPPSSTAK and YDDESWRPLSTVDDH directed against proteins from Human herpesvirus 8, could be found. At 24
months, no matches (using the criteria outlined in materials and methods) between serum CMV epitope recognition and proteomes of other human herpesviruses were
found.
doi:10.1371/journal.pone.0089648.t002
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versus (6 month) post-transplant serum showed no significant
differences concerning CMV peptide recognition using PAM
analysis (see Figure S4).
At 12 months, the humoral CMV-specific response vanished in
all groups with exception of the group were both donor and
recipient were CMV seropositive, most likely reflecting that both
the earlier, older humoral response from the recipient and the new
humoral response from the donor is needed to avoid a general
contraction of the CMV humoral immune system after stem cell
transplantation, when recipient antibody producing cells no longer
persist and no antibody producing donor plasma cells are
functioning yet. This phenomenon was recognized by Wahren
and coworkers almost 20 years ago examining the transfer and
persistence of specific B-cell responses in serologically disparate
donor-recipient pairs [46]. At 24 months after HSCT – as the
donor B-lymphocyte repertoire is being reconstituted - the CMV-
specific humoral immune response was re-established in the
groups that had a contracted humoral response at 12 months
(D2R+ and D+R2). Not mutually exclusive, the T-cell compart-
ment may also contribute to (CMV) antibody diversity: CD8+
TCRalpha/beta repertoire diversity, yet not the magnitude of the
T-cell response, was inversely related to anti-CMV antibody levels
[47]. These results suggested that CD8+ T-cell diversity appears to
be crucial in curbing CMV infections. The association of CMV –
directed humoral and T-cell responses implies that appreciation of
the breadth of humoral immune response, defined by peptide
recognition pattern analysis, may have to be complemented by
TCR CDR3 (complementarity determining region 3) diversity
analysis in CD8+ T-cells from the respective patient.
Anti- glycoprotein B directed antibodies have been incriminated
in anti-virus specific neutralizing capacity, these antibodies differ
in their fine specificity. Target-directed antibody diversity has
clinical consequences (e.g. neutralization), particularly if an
epitope-specific B-cell response arises from a single parental B-
cell clone. This impacts on vaccine development, since vaccines
may not only need to active and expand different B-cell clones, yet
also drive the evolution of single B-cell clones [48]; peptide
microarray technology will therefore help to visualize the antibody
recognition pattern in serum and provide biologically relevant
information whether the anti-CMV directed immune responses is
rather focused, or directed against a broad spectrum of CMV
epitope targets.
Figure 4. Result of the microarray significant profiles analysis (MaSigPro). a) Venn diagram with the number of significant peptides
obtained in the three comparisons (each patient group vs. D2R2. The lists of peptides provided in the Table S5 represents the entire set of peptides
contained in the Venn diagram. These peptides were also grouped into 9 clusters (default value) according to their recognition profile (see Table S5).
b–c) Cluster analyses using CMV peptides that were differentially recognized in serum from patients, based on the D2/R2 status. Three
representative peptide clusters are reported, one for each analysis: D2R+ vs. D2R2 (top), D+R2 vs. D2R2 (middle), D+R+ vs. D2R2 (bottom). b)
The consistency of the CMV epitope response in the cluster is visualized using the continuous peptide recognition profile across all the samples. Each
peptide in the cluster is represented with a different color. c) The group-averaged CMV epitope recognition profiles (for different time points after
HSCT) are shown to visualize differences (between the different patient groups) for CMV peptides selected in each cluster. Each group is represented
with a different color (red =D2R2, green=D2R+, blue =D+R2, cyan=D+R+). Below the figures, peptides in the three clusters are listed. All the
identified clusters and peptides are reported in the Table S4 in greater detail.
doi:10.1371/journal.pone.0089648.g004
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If we hypothesize that the humoral recognition patterns
(displayed in the D2R2 group at different time points after
HSCT) reflects either natural occurring antibodies or ‘‘cross-
reactive’’ antibodies, due to exposure to similar epitopes displayed
by different pathogens or commensal microbes, then a very
focused B-cell recognition would take place if CMV is encountered
from a CMV naı¨ve donor in an CMV+ recipient. Of note, all
CMV epitopes in the highly selective intersection of PAM and the
‘exclusive recognition analysis’ in this patient group (D2R+) at 24
months originate from CMV gene products that have already
been described to stimulate a strong immune response in CD8+
cells (i.e. CMV pp28, CMV pp150 and CMV IE2), reinforcing the
hypothesis that CD8+ immune response and CD4+ immune
responses, providing help to B-cells, are closely orchestrated.
Antibodies against epitopes from closely related amino acid
sequences from different herpesviruses may cross-react [49,50]
and this observation may in part account for the serum recognition
pattern found in the D2R2 group. We identified a higher
percentage of possible CMV peptide targets showing similar
amino acid sequences to other herpesviral species (12.5% and
12.4%) using PAM as well as in the ‘exclusive analysis. If PAM is
combined with the ‘exclusive recognition analysis’ at least 10.4%
of potential cross-reactive epitopes are identified, suggesting that
antibodies directed against the CMV epitope listed in the latter
group may be much more precisely directed against CMV. The
potential cross-reaction with HHV-8 appears to be not that
clinically relevant, since HHV-8 infections are quite rare in the
Swedish population [51]. It is therefore likely that the HHV-8
epitopes, defined in this report, reflect in fact anti-CMV directed
reactivity [52].
During natural CMV infection, potentially neutralizing anti-
bodies targeting CMV glycoproteins, e.g. gH, gB and gM have
been identified [8,10,53]. These target proteins are rather
conserved among human herpesvirus species [54], which might
explain why antibodies recognizing these epitopes (and differen-
tiating the different patient groups) are not found in our study,
since we used the D2R2 group as a negative reference group (see
material and methods section).
Several genetically different CMV strains circulate in the
population [55–58] and the presence of more than one CMV
strain has been observed in immune competent individuals
[59,60]. Therefore, by focusing the statistical analysis on peptides
recognized by all individuals in one group (for serum harvested at
a single time point after HSCT but never in any individual from
the D2R2 group), we postulated that this approach would aid to
antibodies independent of the CMV strain. Due to the use of the
additional analysis with MaSigPro, which considers the dynamics
of the peptide recognition over time, we are able to reliably
identify humoral CMV targets peptides that would distinguish the
seropositive donors/recipients against the D2R2 reference
group. A potential limitation to our findings is clinical course of
CMV infection. We selected a group of long-term survivors and
CMV has a major impact on the survival after allogeneic HSCT
[61]. Thus, our patient group might represent a positive selection.
Our data also show that B-cell responses, identified by peptide
microarrays, may be used to identify functional CD8+ and CD4+
T-cell responses directed against already described and newly
identified cellular CMV targets in PBMCs from patients after
HSCT,. This has to be confirmed with a broader variety of CMV
proteins and with a larger patient cohort - in order to appreciate
the diversity of the immune response in patients with different
genetic backgrounds.
To conclude, CMV epitope proteome mapping aids to describe
the breadth of humoral immune reconstitution after HSCT; it will
also help to map, in an unbiased fashion, immune responses
induced by CMV vaccines in a post-transplant setting.
In the early phase of a CMV infection, antibodies will be
detected to tegument proteins p150 and p65 as well as to non-
Figure 5. Analysis of polyfunctional T cells to previously defined CMV targets and targets defined by peptide array technology.
PBMCs were incubated for 6 hours with the different peptide cocktails and Interleukin-2 (IL-2), interferon-c (IFN-c) and tumor necrosis factor-alpha,
interleukin-17a (IL-17a) productions were measured by intracellular cytokine staining (ICS) on the single-cell level. The cytokine response of one
representative individual is shown.
doi:10.1371/journal.pone.0089648.g005
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structural-proteins IE1 and CM2. Antibodies to glycoproteins gB1
and gB2 are detectable 6–8 weeks after a primary CMV infection.
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